Welcome to our dedicated page for Lantheus Holding SEC filings (Ticker: LNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lantheus Holdings, Inc. (NASDAQ: LNTH) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including Forms 10-K, 10-Q and 8-K. These documents offer detailed information about Lantheus’ radiopharmaceutical-focused business, financial performance, risk factors, leadership changes and material transactions.
In its Form 8-K filings, Lantheus has reported key corporate events such as quarterly and year-to-date financial results, authorization of a stock repurchase program, acquisitions of Evergreen Theragnostics and Life Molecular Imaging, and the divestiture of its SPECT business. Filings also document leadership transitions, including the planned retirement of the Chief Executive Officer, the appointment of an Executive Chairperson and interim CEO, and changes in other senior roles. These disclosures help investors understand governance and compensation arrangements, including consulting and retirement agreements.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via the SEC’s EDGAR system and summarized on this page) typically contain segment information, discussion of products such as PYLARIFY, DEFINITY and Neuraceq, and descriptions of the company’s precision diagnostics, radiopharmaceutical oncology and strategic partnership activities. They also include extensive risk factor sections that discuss competitive dynamics, manufacturing and supply risks, regulatory considerations for PET imaging agents, and integration risks associated with acquisitions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as changes in outlook, major transactions, or updates on radiopharmaceutical pipeline assets like LNTH-2501 and MK-6240. Users can quickly see high-level insights from lengthy 10-K and 10-Q reports, as well as interpret 8-K items related to leadership changes or capital allocation. The filings page also surfaces insider and executive-related information reported in Forms 3, 4 and 5, allowing investors to monitor equity awards, vesting terms and other compensation-related details disclosed for Lantheus executives and directors.
The Vanguard Group filed Amendment No. 8 to Schedule 13G/A reporting zero beneficial ownership of Lantheus Holdings Inc. common stock. The filing states Amount beneficially owned: 0 and Percent of class: 0%. It explains an internal realignment on January 12, 2026 that caused certain Vanguard subsidiaries to report holdings separately.
Lantheus Holdings, Inc. calls its 2026 Annual Meeting of Shareholders for April 30, 2026, asking investors to elect four Class II directors and approve several governance and compensation matters. The board recommends voting for all director nominees, for say‑on‑pay, and for annual future say‑on‑pay votes.
Shareholders are also asked to approve declassifying the board over time, a refreshed 2026 equity incentive plan, and ratification of Deloitte & Touche as auditor. The proxy details a largely independent, skills‑diverse board, strong governance policies, and an executive pay program tied to strategic and operational performance.
The company highlights 2025 strategic moves, including acquiring Life Molecular Imaging and Evergreen Theragnostics, divesting its legacy SPECT business, and advancing a late‑stage radiodiagnostic pipeline with multiple FDA milestones in 2026 across prostate cancer, neuroendocrine tumors, and Alzheimer’s disease imaging.
Lantheus Holdings is soliciting votes for its 2026 Annual Meeting and outlines strategic, operational and governance priorities while reporting key portfolio moves and regulatory milestones. The company says its products impacted ~7M patients in 2025 and highlights two acquisitions—Life Molecular Imaging (now Lantheus Biosciences) and Evergreen Theragnostics—plus the divestiture of its legacy SPECT business, effective January 1, 2026.
The proxy notes commercial momentum for PYLARIFY and Neuraceq, and lists near-term regulatory milestones: PYLARIFY TruVu FDA approval in March (day redacted) with a regionally phased launch beginning in 4Q 2026; PNT2003 received tentative ANDA approval in February 2026; OCTEVY has a PDUFA date of March 29; and MK6240 has a PDUFA date of August 13. The Board is conducting a CEO search; Mary Anne Heino is Executive Chairperson and Interim CEO.
Lantheus Holdings, Inc. officer Daniel Niedzwiecki received an equity award of 36,692 shares of common stock on March 5, 2026 at a stated price of $0.00 per share. This consists of 18,346 restricted stock units that vest in equal installments over three years and 18,346 performance-based PSUs that cliff vest after a three-year performance period, with the final PSU amount adjustable between 0% and 200% of target based on performance. On the same date, 1,283 shares were disposed of at $76.31 per share to cover taxes, leaving him with 119,376 shares of common stock held directly following these transactions.
Dinkelborg Ludger reported acquisition or exercise transactions in this Form 4 filing.
Lantheus Holdings executive Ludger Dinkelborg received an equity award of 20,966 shares of common stock on March 5, 2026 at no purchase cost. After this grant, his directly held common stock totaled 35,731 shares.
The award consists of 10,483 restricted stock units that vest in equal installments over three years and 10,483 Total Shareholder Return performance-based restricted stock units that cliff vest after a three-year performance period. The performance-based units can ultimately settle at 0% to 200% of the target amount depending on results.
Lantheus Holdings CFO Robert J. Marshall Jr. reported equity awards and related tax withholding in company stock. He acquired 38,002 shares of common stock on March 5, 2026 at a stated price of $0.00 per share as a grant or award.
The award consists of 19,001 restricted stock units that vest in equal installments over three years and 19,001 Total Shareholder Return performance-based restricted stock units that cliff vest after a three-year performance period, with the final PSU award ranging from 0% to 200% of the target. On the same date, 1,182 shares were disposed of at $76.31 per share to cover tax obligations, leaving him with 122,792 directly owned shares of common stock after these transactions.
Lantheus Holdings, Inc. Chief Accounting Officer Kimberly Brown reported equity compensation and a related tax-withholding transaction in common stock. On March 5, 2026, she acquired 6,158 shares at $0.00 per share as a grant, consisting of 3,079 restricted stock units vesting over three years and 3,079 performance-based PSUs that cliff vest after a three-year performance period, with the final PSU amount ranging from 0% to 200% of target based on results. On the same date, 133 shares were disposed of at $76.31 per share for tax withholding. Following these transactions, she directly owned 13,726 common shares.
Lantheus Holdings, Inc. Chief Commercial Officer Amanda Michelle Morgan reported equity compensation and related tax withholding transactions in company common stock. She received a grant of 26,208 shares at no cost, consisting of 13,104 restricted stock units and 13,104 performance-based PSUs that vest over a three-year period.
The Form 4 also shows a disposition of 595 shares at $76.31 per share to satisfy tax obligations through share withholding, not an open-market sale. After these transactions, she directly holds 64,153 shares of Lantheus common stock.
Lantheus Holdings, Inc. reported that officer Daniel Niedzwiecki received 5,169 shares of common stock on March 2, 2026 at no cost, reflecting additional shares from performance-based PSUs that vested above target. On the same date, 8,259 shares were disposed of at $76.30 per share to cover tax obligations, leaving him with 83,967 directly held shares.